
    
      Subjects enrolled to assess safety will receive a combination of Gemcitabine plus RX-0201.
      Gemcitabine will be administered prior to RX-0201 intravenously in a 30-min iv infusion dose
      at 1000 mg/m2 once weekly for up to 2 cycles; each 4-week cycle consist of 3-week treatment
      phase followed by 1 week resting phase. RX-0201 will be administered at 250 mg/m2/day in a
      24-hour continuous intravenous infusion for up to 2 cycles; each 3-week cycle consists of
      2-week treatment phase followed by a 1 week resting phase. (See schedule of
      assessments)Subjects enrolled to evaluate efficacy will receive a combination of Gemcitabine
      and RX-0201 as outline above for up to 4 cycles.
    
  